<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04048889</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00655</org_study_id>
    <nct_id>NCT04048889</nct_id>
  </id_info>
  <brief_title>Addition of Popliteal Plexus Block to Continuous Femoral Nerve Block for Total Knee Arthroplasty</brief_title>
  <official_title>Addition of Popliteal Plexus Block to Continuous Femoral Nerve Block for Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The popliteal plexus block has been described as an alternative analgesic postoperative pain
      treatment for total knee arthroplasty. It consists of injecting local anaeshetics inside the
      distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral
      artery, between the medial vastus muscle and the adductor magnus muscle, in order to
      anesthetize the popliteal plexus. However, the analgesic efficacy has never been demonstrated
      in a randomized controlled trial. Therefore the objective of this study is to investigate the
      analgesic benefit of this block combined with a continuous femoral nerve block, on patients
      scheduled for total knee athroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients scheduled to undergo total knee arthroplasty under general anesthesia will be
      randomly allocated to two groups: continuous femoral nerve block alone or continuous femoral
      nerve block with addition of a popliteal plexus block.

      The continuous femoral nerve block will be performed by the anesthesiologist with 15 mLs of
      ropivacaine 0.5%, under ultrasound guidance before the beginning of the general anesthesia.
      The popliteal plexus block will be done by the anesthesiology, under ultrasound guidance,
      before the beginning of the surgery, under general anesthesia.

      Postoperative analgesia will include acetaminophen (4 x 1000 mg), ibuprofen (3 x 400 mg) and
      a continuous infusion of Ropivacaine 0.2%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled triple-blinded trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total iv morphine consumption (mg)</measure>
    <time_frame>12 postoperative hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total iv morphine consumption (mg)</measure>
    <time_frame>24 and 48 postoperative hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average and maximum pain scores (Numeric rating scale 0-10)</measure>
    <time_frame>12, 24 and 48 postoperative hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sciatic extension of popliteal plexus block</measure>
    <time_frame>2 and 24 postoperative hours</time_frame>
    <description>Presence of sensitive or/and motor sciatic extension of popliteal plexus block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plantarflexion and dorsiflexion ankle strength (Newtons)</measure>
    <time_frame>2 and 24 postoperative hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee pain localization (anterior, internal, posterior, lateral, medial)</measure>
    <time_frame>2, 12, 24 and 48 postoperative hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Popliteal plexus block procedure time (minutes)</measure>
    <time_frame>When performing the popliteal plexus block</time_frame>
    <description>Onset of action = beginning of the disinfection; End of action = end of injection of 15 mls of Ropivacain 0.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Popliteal plexus block duration of action (hours)</measure>
    <time_frame>up to 48 postoperative hours</time_frame>
    <description>Onset of action = Time from end of infection of 15 mls of Ropivacain 0.5%; End of action = onset of lateral and/or posterior knee pain (With Numeric rating scale ≥ 4)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Popliteal plexus block and continuous femoral nerve block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>continuous femoral nerve block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.5% Injectable Solution</intervention_name>
    <description>Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca</description>
    <arm_group_label>continuous femoral nerve block</arm_group_label>
    <other_name>Continous femoral nerve block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.5% Injectable Solution</intervention_name>
    <description>Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.</description>
    <arm_group_label>Popliteal plexus block and continuous femoral nerve block</arm_group_label>
    <other_name>Continous femoral nerve block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.5% Injectable Solution</intervention_name>
    <description>Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.</description>
    <arm_group_label>Popliteal plexus block and continuous femoral nerve block</arm_group_label>
    <other_name>Popliteal plexus block</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for total knee athroplasty under general anesthesia

          -  ASA 1-3

        Exclusion Criteria:

          -  Kidney disease with GFR &lt; 50 ml/mn

          -  Daily opioid consumption &gt; 1 month

          -  Allergy to local anesthetics

          -  Neurological problems of the lower extremity

          -  other contraindications to peripheral nerve blocks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kevin Stebler, MD</last_name>
    <phone>0041795532149</phone>
    <email>kevin.stebler@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Departement of Anesthesia, Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Stebler, MD</last_name>
      <phone>0041795532149</phone>
      <email>kevin.stebler@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Roxane Fournier, PD</last_name>
      <phone>0041795532058</phone>
      <email>roxabe.fournier@hcuge.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Kevin Stebler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

